

1 **Manuscript title: Loss in the expansion of SARS-CoV-2 specific immunity is a key risk**  
2 **factor in fatal patients with COVID-19**

3

4 Qiang Zeng, MD<sup>#</sup>, Gang Huang, MD<sup>#</sup>, Yong-zhe Li, MD<sup>#</sup>, Guoqiang Xu, PhD, Sheng-yong Dong,  
5 MD, Tian-yu Zhong, MD, Zong-tao Chen, MD, Yang Xu, MD, PhD<sup>\*</sup>

6 **Authors' name and affiliations:**

7 Chinese PLA General Hospital, Beijing, China (Q. Zeng, S.Y. Dong); Shanghai University of  
8 Medicine and Health Sciences, Shanghai, China (G. Huang, Y. Xu); Jiangsu Key Laboratory of  
9 Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China  
10 (G. Xu); First Affiliated Hospital, Gannan Medical University, Ganzhou, China (T.Y. Zhong); The  
11 first affiliated Hospital, Army Medical University, Chongqing, China (Z.T. Chen); Department of  
12 Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China (Y.Z. Li).

13

14 **\* Contact information for the corresponding author:**

15 Yang Xu, MD, PhD, Director

16 Laboratory of Special Diagnosis

17 Shanghai University of Medicine and Health Sciences

18 Shanghai 201318, China

19 E-mail: [yxu1627@126.com](mailto:yxu1627@126.com)

20

21

22 **Highlights**

23

24 ● **The immune system and function gradually remodeled and declined with**  
25 **age.**

26 ● **SARS-CoV-2-specific immunity declined with age in fatal cases.**

27 ● **SARS-CoV-2-specific immunity was associated with survival time in fatal**  
28 **cases.**

29 ● **Loss in the expansion of SARS-CoV-2-specific immunity could be expanded**  
30 ***in vitro*.**

31 ● **A concurrent decline in SARS-CoV-2-specific cellular and humoral**  
32 **immunities and prolonged SARS-CoV-2 exposure predicted fatal outcomes.**

33

34

35

36

37

38

39

40

41

42 **Keywords**

43 CD4; CD8; COVID-19; Expansion; IFN $\gamma$ ; SARS-CoV-2 specific immunity; SARS-CoV-2; T cells

44 **ABSTRACT**

45 Knowledge of the dynamic immunological characteristics of patients with coronavirus  
46 disease 2019 (COVID-19) is essential for clinicians to understand the progression of  
47 the disease. Our data showed that the immune system and function gradually  
48 remodeled and declined with age, starting from age 16 until age 91 in 25,239 healthy  
49 controls. An analysis of the relationship between the number of lymphocytes and age  
50 revealed that the lymphocyte and subset counts tended to decline with age  
51 significantly. Severe acute respiratory syndrome coronavirus 2  
52 (SARS-CoV-2)-specific immunity declined with age and was associated with survival  
53 time in fatal cases. Loss in the expansion of SARS-CoV-2-specific immunity could be  
54 expanded *in vitro*. The concurrent decline in SARS-CoV-2-specific cellular and  
55 humoral immunities and prolonged SARS-CoV-2 exposure predicted fatal outcomes.  
56 Our findings provide a basis for further analysis of SARS-CoV-2-specific immunity  
57 and understanding of the pathogenesis of fatal COVID-19 cases.

58

59

60

61

62

63

64

65

## 66 INTRODUCTION

67 Coronavirus disease 2019 (COVID-19) pandemic leads to severe illness, life-threatening  
68 complications, and death, especially in high-risk groups such as elderly people and individuals  
69 with comorbidities<sup>1-7</sup>. However, information on immunological characteristics in the assessment  
70 of COVID-19 for frontline clinicians is limited. The objective of this study is to explore the  
71 dynamic immunological characteristics as the disease progresses.

72 In January, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was  
73 identified in samples of bronchoalveolar lavage fluid from patients in Wuhan, China, and was  
74 confirmed as the cause of the SARS-CoV-2 pneumonia<sup>1,2</sup>. Full-genome sequencing and  
75 phylogenic analysis indicated that SARS-CoV-2 is a distinct clade from the betacoronaviruses  
76 associated with human SARS and Middle East respiratory syndrome (MERS)<sup>1,2</sup>.

77

78 COVID-19 has spread rapidly since it was first identified in Wuhan and has been shown to have a  
79 wide spectrum of severity. Recently, a report shows that SARS-CoV and SARS-CoV-2 shared the  
80 same functional host-cell receptor, angiotensin-converting enzyme 2 (ACE2)<sup>8</sup>. Furthermore,  
81 SARS-CoV-2 binds to ACE2 receptors in 10-20 fold higher affinity than SARS-CoV binds to the  
82 same receptors<sup>8</sup>. The receptor binding domain is recognized by the extracellular peptidase domain  
83 of ACE2 mainly through polar residues, which provide important insights into the molecular basis  
84 for coronavirus recognition and infection<sup>9</sup>. Since ACE2 receptors on lung alveolar epithelial cells  
85 and enterocytes of the small intestine are highly expressed, lung alveolar epithelial cells or  
86 enterocytes of the small intestine may be an important source of infection<sup>10</sup>.

87 According to World Health Organization (WHO) interim guidance on January 12, 2020,  
88 SARS-CoV-2 infection is classified as asymptomatic, mild, severe, and critical cases of  
89 pneumonia (acute respiratory distress syndrome [ARDS], sepsis, septic shock). Severe cases of  
90 pneumonia are defined as patients with respiratory rate > 30 breaths/min, severe respiratory  
91 distress, or peripheral capillary oxygen saturation < 90% on room air<sup>11</sup>. Asymptomatic cases have  
92 been reported in China and Germany<sup>12,13</sup>. Huang et al.<sup>2</sup> first reported 41 cases of SARS-CoV-2  
93 pneumonia in which most patients had a history of exposure to Huanan Seafood Wholesale  
94 Market. Organ dysfunction (shock, ARDS, acute cardiac injury, and acute kidney injury, etc.) and  
95 death can occur in severe or critical cases. Guan et al.<sup>3</sup> reported findings from 1,099 cases of  
96 SARS-CoV-2 pneumonia and the results suggested that the SARS-CoV-2 infection clustered  
97 within groups of people in close contact, and was more likely to affect the old with comorbidities.  
98 However, there is no pre-existing antibody-mediated immunity to SARS-CoV-2 at the population  
99 level, leading to more than half million deaths and 10 millions of infections which have been  
100 reported worldwide as of June 29, 2020<sup>14</sup>.

101 The disease severity is associated with immune dysregulation, for example, dysregulation of T  
102 cells, or associated with macrophage activation syndrome<sup>15-21</sup>. Grifoni et al.<sup>22</sup> reported  
103 SARS-CoV-2-specific CD4 and CD8 T cells responses in 20 recovery cases of COVID-19. Using  
104 multiple experimental approaches, SARS-CoV-2-specific CD4 T cell and antibody responses were  
105 observed in all COVID-19 patients and SARS-CoV-2-specific CD8 T cell responses were seen in  
106 most COVID-19 patients. All of the patients had SARS-CoV-2-specific CD4 T cells that  
107 recognized the virus's spike protein, and 70% of them had SARS-CoV-2-specific CD8 T cells that  
108 responded to the same protein. The identification of strong T cell responses in recovered

109 COVID-19 patients promotes further study in designing vaccines to induce T cell responses. Ni et  
110 al.<sup>18</sup> also observed SARS-CoV-2-specific humoral and cellular immunity in 14 convalescent  
111 patients. However, to the best of our knowledge, SARS-CoV-2-specific CD4 and CD8 T cell  
112 responses in fatal cases of COVID-19 were not reported. Furthermore, understanding the key  
113 immune mechanisms to recover from novel SARS-CoV-2 exposure is an urgent need.

114 It is important to understand the key risk factors of critical patients who died. We hypothesize that  
115 lethal COVID-19 disease would be associated with immune dysregulation and loss expansion of  
116 SARS-CoV-2-specific immunity. Here, we analyzed dynamic immunological characteristics in  
117 fatal COVID-19 patients in a unique longitudinal cohort of samples.

## 118 **RESULTS**

119

### 120 **The immune system and function gradually remodeled and declined with age in** 121 **25,239 healthy controls.**

122 The numbers of lymphocytes and subset counts, except for natural killer (NK) cells,  
123 tended to decline with age significantly (Spearman  $R = -$  [range, 0.9048–1],  $P < 0.001$ ,  
124 Figure 1A–E and Table S2). However, the relationship between the number of NK  
125 cells and age only showed a tendency of the NK cells to increase in number with age  
126 (Spearman  $R = 0.6429$ ,  $P = 0.0962$ , Figure 1F and Table S2).

127

### 128 **SARS-CoV-2-specific immunity declined with age in fatal COVID-19 cases**

129 The SARS-CoV-2-specific immunity tended to decline with age (Figure 2A–C).

130 However, the virus load tended to increase with age (Figure 2D).

131 The ability to expand SARS-CoV-2-specific interferon gamma (IFN $\gamma$ )+CD4+ T cells  
132 (Spearman  $R = -0.8020$ ,  $P < 0.0001$ , Figure 2A) and IFN $\gamma$ +CD8+ T cells (Spearman  $R$   
133  $= -0.8028$ ,  $P < 0.0001$ , Figure 2B) was significantly inversely related to age. This  
134 suggests that the elderly had low expansion ability of SARS-CoV-2-specific T-cell  
135 immunity, which led to the faster progression of the disease to a severe illness, an  
136 important risk factor of mortality in the elderly. SARS-CoV-2-specific humoral  
137 immunity (Spearman  $R = -0.2671$ ,  $P = 0.0254$ , Figure 2C) was also inversely related  
138 to age. However, this relationship was weaker than that of SARS-CoV-2-specific  
139 T-cell immunity with age. The SARS-CoV-2 viral load was directly and significantly  
140 proportional to age (Spearman  $R = 0.4780$ ,  $P < 0.0001$ , Figure 2D). This suggests that  
141 the elderly easily contracted the infection or that the patients had a higher viral load in  
142 the body.

143 **SARS-CoV-2-specific immunity is associated with survival time in fatal**  
144 **COVID-19 cases**

145 As the survival time increased, the SARS-CoV-2-specific immunity tended to increase.  
146 However, the relationship between virus load and survival time showed that the virus  
147 load tended to decrease as the survival time increased (Figure 3).

148

149 The correlations between SARS-CoV-2-specific IFN $\gamma$ +CD4+ T cells (Spearman  $R =$   
150  $0.7655$ ,  $P < 0.0001$ , Figure 3A) and IFN $\gamma$ +CD8+ T cells (Spearman  $R = 0.7623$ ,  $P <$

151 0.0001, Figure 3B) and survival time were relatively strong and significant,  
152 suggesting that the patient's survival time depended on the expansion ability of  
153 SARS-CoV-2-specific T-cell immunity. The aggregated data for 4 weeks showed that  
154 SARS-CoV-2-specific humoral immunity was significantly related to survival time  
155 (Spearman  $R = 0.7924$ ,  $P < 0.0001$ , Figure 3C). The SARS-CoV-2 viral load was  
156 inversely proportional to survival time (Spearman  $R = -0.4730$ ,  $P < 0.0001$ , Figure  
157 3D). This suggests that the higher the viral load of SARS-CoV-2, the shorter the  
158 survival time of the patient. Therefore, controlling the replication of the virus might  
159 prolong the survival time of patients.

160

161 We found no significant difference in the frequency of SARS-CoV-2-specific  
162  $\text{IFN}\gamma\text{+CD4}^+$  T cells (Figure 4A) between the first and second weeks. However,  
163 significant differences were observed between the first and third or fourth weeks,  
164 possibly indicating that SARS-CoV-2-specific  $\text{IFN}\gamma\text{+CD4}^+$  T cells began to expand in  
165 the third week significantly (Figure 4A). No significant difference in the frequency of  
166 SARS-CoV-2 specific  $\text{IFN}\gamma\text{+CD8}^+$  T cells was found between the first and second,  
167 third, or fourth weeks, indicating that the expansion of the specific CD8 T cells was  
168 lost (Figure 4B). A significant difference in the titer of the specific IgG antibodies was  
169 found between the first and second weeks. Compared with that at week 1, the IgG  
170 titer in weeks 2–4 continued to show significant differences, which suggests that the  
171 SARS-CoV-2-specific antibodies began to expand in the second week, but the  
172 antibody titer was low (Figure 4C). Significant differences were found between the



173 viral loads from weeks 1 to 4 (Figure 4D), indicating that the SARS-CoV-2-specific  
174 immunity could potentially clear the SARS-CoV-2 replication in fatal cases. However,  
175 the SARS-CoV-2-specific immunity was unable to clear all SARS-CoV-2 replications  
176 in the fatal cases. The mean viral load was  $6.7 \times 10^4$  copies/mL at week 3, indicating  
177 the presence of persistent SARS-CoV-2 infection.

178

179 **The loss in the expansion of SARS-CoV-2-specific immunity in the fatal cases**  
180 **could be expanded *in vitro***

181 From our results, we can infer that the key factor was loss in the expansion of  
182 SARS-CoV-2-specific humoral and cellular immunities, causing the virus to remain in  
183 the body in fatal cases. As the expansion of SARS-CoV-2-specific immunity started  
184 from the first 2–3 weeks, we chose peripheral blood mononuclear cells (PMBCs) in  
185 the third week for the expansion experiment *in vitro*. Our data showed that these  
186 PMBCs could be expanded *in vitro*. After the expansion, SARS-CoV-2-specific  
187 IFN $\gamma$ +CD4 $^+$  T cells and IFN $\gamma$ +CD8 $^+$  T cells increased significantly (Figure 5). This  
188 suggests that the SARS-CoV-2-specific immunity lost its expansion in the 21 fatal  
189 cases at week 3, but the expansion of the SARS-CoV-2-specific cellular immunity  
190 was recovered in the *in vitro* experiment (Figure 5).

191

192 **A concurrent decline in SARS-CoV-2-specific cellular and humoral immunities**  
193 **and prolonged SARS-CoV-2 exposure predicted fatal outcomes**

194

195 Significant correlations were observed between SARS-CoV-2-specific IFN $\gamma$ +CD4 $^+$  T  
196 cells (Spearman  $R = 0.4537$ ,  $P < 0.0001$ , Figure 6A) and IFN $\gamma$ +CD8 $^+$  T cells  
197 (Spearman  $R = 0.3721$ ,  $P = 0.0002$ , Figure 6B) and SARS-CoV-2-specific humoral  
198 immunity.

199

200 SARS-CoV-2-specific IFN $\gamma$ +CD4 $^+$  T cells (Spearman  $R = -0.4784$ ,  $P < 0.0001$ ,  
201 Figure 7A) and IFN $\gamma$ +CD8 $^+$  T cells (Spearman  $R = -0.4609$ ,  $P < 0.0001$ , Figure 7B)  
202 inversely correlated significantly with the SARS-CoV-2 viral load, which suggests  
203 that the SARS-CoV-2-specific T-cell immunity plays a leading role in viral clearance.

204

205 SARS-CoV-2-specific humoral immunity inversely correlated significantly with  
206 SARS-CoV-2 viral load, which suggests that SARS-CoV-2-specific humoral  
207 immunity played a role in viral clearance (Figure 8). However, the  $R$  value of  
208 SARS-CoV-2-specific humoral immunity was smaller than that of  
209 SARS-CoV-2-specific T-cell immunity (Figures 7 and 8), which suggests that  
210 SARS-CoV-2-specific T-cell immunity might play a major role in viral clearance in  
211 fatal cases.

212

213 However, the proportion of patients with SARS-CoV-2-specific T cells was  
214 significantly lower than that of COVID-19 survivors (Figure 9A, 9B), which suggests  
215 a loss in the expansion of the SARS-CoV-2-specific cellular immunity in fatal cases.

216 In addition, the IgG titer was significantly lower than that in COVID-19 survivors

217 (Figure 9C), which suggests a loss in the expansion of SARS-CoV-2-specific humoral  
218 immunity in the fatal cases. Here, we define "loss in the expansion" as a decrease in  
219 SARS-CoV-2-specific immunity in fatal cases compared to survivors of critical  
220 COVID-19 cases.

221

222 Furthermore, SARS-CoV-2-specific immunity was unable to clear the SARS-CoV-2  
223 replications in the fatal cases. All the patients had a positive viral load before death,  
224 which suggests that prolonged SARS-CoV-2 exposure can predict fatal outcomes  
225 (Figure 4D).

226

## 227 **DISCUSSION**

228

229 The extent of lymphopenia in patients admitted to the intensive care unit correlates  
230 with COVID-19 severity and mortality<sup>23-26</sup>. Therefore, studies of the immune system  
231 and function in healthy controls are important to understand whether the immune  
232 system and function is related to age. Our data showed that the immune system and  
233 function have gradually remodeled and declined with age in 25,239 healthy controls.

234 Channappanavar et al.<sup>27</sup> reported that SARS-CoV-specific memory CD8 T cells  
235 persisted for up to 6 years after SARS-CoV infection. When challenge with a lethal  
236 dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced IFN $\gamma$ ,  
237 tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), etc. and reduced lung viral load. Next, we tried to  
238 understand whether SARS-CoV-2-specific immunity is associated with age in those

239 fatal patients with COVID-19. Our data suggested that SARS-CoV-2-specific  
240 immunity has declined with age in COVID-19 patients.

241 Levels of lymphocytes and lymphocyte subsets are of great importance to keep the  
242 immune system working. Usually viral infection, immunodeficiency diseases, and  
243 other infectious diseases lead to abnormal changes in the levels of lymphocyte  
244 subsets<sup>16</sup>. Although SARS-CoV-2 has been identified as the causative agent of  
245 COVID-19, the mechanism by which SARS-CoV-2 impacts the human immune  
246 system is still unclear<sup>16</sup>.

247 Grifoni et al.<sup>22</sup> reported SARS-CoV-2-specific CD4 and CD8 T cells responses in 20  
248 recovery cases of COVID-19. SARS-CoV-2-specific CD4 T cell and antibody  
249 responses were observed in all COVID-19 patients and SARS-CoV-2-specific CD8 T  
250 cell responses were seen in most COVID-19 patients. Ni et al.<sup>18</sup> also observed  
251 SARS-CoV-2-specific humoral and cellular immunity in 14 convalescent patients. We  
252 explored whether SARS-CoV-2-specific immunity is associated with survival time in  
253 those fatal patients with COVID-19. Our data showed that SARS-CoV-2 specific  
254 immunity was associated with survival time in COVID-19 patients. Our results were  
255 consistent with previous reports<sup>18,22</sup>.

256

257 From the above results, it can be known that the key factor was loss in the expansion  
258 of SARS-CoV-2-specific humoral and cellular immunity and the virus cannot be  
259 eliminated from the body in fatal cases. We tried to understand whether loss in the

260 expansion of SARS-CoV-2-specific immunity in fatal cases could be expanded *in*  
261 *vitro*. Since the expansion of SARS-CoV-2-specific immunity started from the first  
262 2-3 weeks, we chose PMBCs in the third week for the expansion experiment *in vitro*.  
263 Our data showed that these PBMCs could be expanded *in vitro*. After the expansion,  
264 SARS-CoV-2-specific IFN $\gamma$ +CD4<sup>+</sup> T cells and IFN $\gamma$ +CD8<sup>+</sup> T cells increased  
265 significantly. It suggested that the SARS-CoV-2-specific immunity of these fatal  
266 patients lost their expansion, but the expansion of SARS-CoV-2-specific cellular  
267 immunity could be recovered *in vitro* experiment.

268

269 Our data indicated that a concurrent decline in SARS-CoV-2 specific cellular and  
270 humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes.  
271 First, the immune system and function have gradually remodeled and declined with  
272 age in healthy controls. Therefore, the elderly are susceptible to the SARS-CoV-2.  
273 Second, our data showed that SARS-CoV-2-specific immunity has declined with age  
274 in COVID-19 patients. Therefore, the elderly easily turned from mild to severe  
275 SARS-CoV-2 infections. Those results have explained that the elderly is a risk factor  
276 for poor outcomes. Third, our data further showed that SARS-CoV-2-specific  
277 immunity is associated with survival time in COVID-19 patients. The correlation  
278 between SARS-CoV-2-specific IFN $\gamma$ +CD4<sup>+</sup> T cells and IFN $\gamma$ +CD8<sup>+</sup> T cells and  
279 survival time was relatively strong, and significantly correlated with survival time,  
280 suggesting that patient survival time depended on the expansion ability of  
281 SARS-CoV-2-specific T cell immunity. The aggregated data for 4 weeks showed that

282 SARS-CoV-2-specific humoral immunity was related to survival time. SARS-CoV-2  
283 viral load was inversely proportional to survival time significantly. It suggested that  
284 the higher the viral load of SARS-CoV-2, the shorter the survival time of patients.  
285 Therefore, controlling the replication of the virus might prolong the survival time of  
286 patients. Finally, we observed that a concurrent decline in SARS-CoV-2-specific  
287 cellular and humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal  
288 outcomes. There was significant correlation between SARS-CoV-2-specific T cell  
289 immunity and SARS-CoV-2-specific humoral immunity. The frequency of  
290 SARS-CoV-2-specific T cells and titer of IgG were much lower than that of survivors  
291 of critical COVID-19 cases and there were higher viral load in the course of the  
292 disease, indicating that the persistent SARS-CoV-2 infection and loss in the expansion  
293 of SARS-CoV-2-specific immunity are important factors.

294

295

296

297

298

299

300

301

302

303

304 **Acknowledgments**

305 The work was supported in part by the National Natural Science Foundation of China (Grant No.  
306 81830052 and 81530053).

307 **Author contributions**

308 <sup>#</sup>Drs. Q Zeng, G Huang and YZ Li contributed equally to this article and share first authorship.

309 \* Correspondence to Dr. Y Xu.

310

311 Q Zeng, G Huang and YZ Li contributed to study design, data interpretation, and manuscript  
312 drafting. GX, ZTC, ZTC contributed to data analysis, figure preparation, the literature search, and  
313 manuscript drafting. SYD and GX contributed to performed experiments, data collection, data  
314 analysis, and figure preparation. YX contributed to study design and reviewed the final draft. All  
315 authors read and approved the manuscript.

316

317 **Competing interests statement**

318 We declare no competing interests.

319

320

321

322

323

324

325

326 **References**

- 327 1. Zhu, N., *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl.J.*  
328 *Med.* **382**, 727-733 (2020).
- 329 2. Huang, C., *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,  
330 China. *Lancet (London, England)* **395**, 497-506 (2020).
- 331 3. Guan, W.J., *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl.J.*  
332 *Med.* **382**, 1708-1720 (2020).
- 333 4. Li, Q., *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected  
334 pneumonia. *N. Engl.J. Med.* **382**, 1199-1207 (2020).
- 335 5. Wang, D., *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel  
336 coronavirus-infected pneumonia in Wuhan, China. *JAMA* **323**, 1061-1069 (2020).
- 337 6. Zhou, F., *et al.* Clinical course and risk factors for mortality of adult in patients with  
338 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)* **395**,  
339 1054-1062 (2020).
- 340 7. Wu C, Chen X, Cai Y, *et al.* Risk factors associated with acute respiratory distress syndrome  
341 and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA*  
342 *Intern Med.* **180**, 934-943 (2020).
- 343 8. Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.  
344 *Science (New York, N.Y.)* **367**, 1260-1263 (2020).
- 345 9. Yan, R., *et al.* Structural basis for the recognition of SARS-CoV-2 by full-length human  
346 ACE2. *Science (New York, N.Y.)* **367**, 1444-1448 (2020).
- 347 10. Hamming, I., *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS



- 348 coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **203**, 631-637  
349 (2004).
- 350 11. World Health Organization. Clinical management of severe acute respiratory infection when  
351 novel coronavirus (nCoV) infection is suspected. *Interim guidance on January 12, 2020*  
352 (*accessed February 15*), <https://apps.who.int/iris/handle/10665/330854> (2020).
- 353 12. Pan, X., *et al.* Asymptomatic cases in a family cluster with SARS-CoV-2 infection. *Lancet*  
354 *Infect. Dis.* **20**, 410-411 (2020).
- 355 13. Rothe, C., *et al.* Transmission of 2019-nCoV infection from an asymptomatic contact in  
356 Germany. *N. Engl. J. Med.* **382**, 970-971 (2020).
- 357 14. WHO. Rolling updates on coronavirus disease (COVID-19).  
358 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (*accessed June 29, 2020*)  
359 (2020).
- 360 15. Xu, Z., *et al.* Pathological findings of COVID-19 associated with acute respiratory distress  
361 syndrome. *Lancet Respir. Med.* **8**, 420-422 (2020).
- 362 16. Vabret, N., *et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**,  
363 910-941 (2020).
- 364 17. Diao, B., *et al.* Reduction and functional exhaustion of T cells in patients with coronavirus  
365 disease 2019 (COVID-19). *Front. Immunol.* **11**, 827 (2020).
- 366 18. Ni, L., *et al.* Detection of SARS-CoV-2-specific humoral and cellular immunity in  
367 COVID-19 convalescent individuals. *Immunity* **52**, 971-977.e973 (2020).
- 368 19. Giamarellos-Bourboulis, E.J., *et al.* Complex immune dysregulation in COVID-19 patients  
369 with severe respiratory failure. *Cell Host Microbe* **27**, 992-1000.e1003 (2020).

- 370 20. Day, C.L., *et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion  
371 and disease progression. *Nature* **443**, 350-354 (2006).
- 372 21. Trautmann, L., *et al.* Upregulation of PD-1 expression on HIV-specific CD8<sup>+</sup> T cells leads to  
373 reversible immune dysfunction. *Nat. Med.* **12**, 1198-1202 (2006).
- 374 22. Grifoni, A., *et al.* Targets of T cell responses to SARS-CoV-2 coronavirus in humans with  
375 COVID-19 disease and unexposed individuals. *Cell* **181**, 1489-1501.e1415 (2020).
- 376 23. Chen, G., *et al.* Clinical and immunological features of severe and moderate coronavirus  
377 disease 2019. *J. Clin. Invest.* **130**, 2620-2629 (2020).
- 378 24. Liu, J., *et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in  
379 the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* **55**, 102763 (2020).
- 380 25. Tan, L., *et al.* Lymphopenia predicts disease severity of COVID-19: a descriptive and  
381 predictive study. *Signal. Transduct. Target. Ther.* **5**, 33 (2020).
- 382 26. Wang, F., *et al.* Characteristics of peripheral lymphocyte subset alteration in COVID-19  
383 pneumonia. *J. Infect. Dis.* **221**, 1762-1769 (2020).
- 384 27. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D.K. & Perlman, S. Virus-specific  
385 memory CD8 T cells provide substantial protection from lethal severe acute respiratory  
386 syndrome coronavirus infection. *J. Virol.* **88**, 11034-11044 (2014).

387

388

389

390

391

392 **Figures and Legends**

393

394 **Figure 1. Dynamic distribution of lymphocytes and subsets according to age**  
395 **among the 25,239 healthy controls.** We enrolled laboratory data from 25,239 health  
396 controls in November 2017 and November 2019 from health check up before  
397 the COVID-19 pandemic.

398

399 **Figure 2. Dynamic distribution of severe acute respiratory syndrome coronavirus**  
400 **2 (SARS-CoV-2)-specific immunity and viral load according to age among the**  
401 **fatal cases.**

402

403 **Figure 3. Dynamic distribution of severe acute respiratory syndrome**  
404 **coronavirus2 (SARS-CoV-2)-specific immunity and viral load according to**  
405 **survival time among the fatal cases.**

406

407 **Figure 4. Dynamic characteristics of severe acute respiratory syndrome**  
408 **coronavirus 2 (SARS-CoV-2)-specific immunity and viral load in the fatal cases.**

409 ns,  $P > 0.05$ ; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .

410

411 **Figure 5. Peripheral blood mononuclear cells (PBMCs) of the 21 fatal cases at**  
412 **week 3 stimulated with severe acute respiratory syndromecoronavirus2**  
413 **(SARS-CoV-2) spike glycoprotein peptide pools (SPs).** The graph showed the

414 percentage of SARS-CoV-2 specific IFN $\gamma$ +CD4+T cells (A) and SARS-CoV-2  
415 specific IFN $\gamma$ +CD8+ T cells (B) reactive to the SPs directly *ex vivo* (w/o expansion)  
416 and after *in vitro* expansion (expansion). \*\*,  $P=0.0017$ ; \*\*\*\*,  $P<0.0001$ .

417

418 **Figure 6. Severe acute respiratory syndrome coronavirus 2**  
419 **(SARS-CoV-2)-specific T-cell immunity (interferon [IFN] $\gamma$ +CD8+ and**  
420 **IFN $\gamma$ +CD4+) showing no correlation with SARS-CoV-2-specific humoral**  
421 **immunity.**

422

423 **Figure 7. Inverse correlation of severe acute respiratory syndrome coronavirus 2**  
424 **(SARS-CoV-2)-specific T-cell immunity (interferon [IFN] $\gamma$ +CD8+ and**  
425 **IFN $\gamma$ +CD4+) with SARS-CoV-2 viral load.**

426

427 **Figure 8. Inverse correlation of severe acute respiratory syndrome coronavirus 2**  
428 **(SARS-CoV-2)-specific humoral immunity (IgG) with SARS-CoV-2 viral load.**

429

430 **Figure 9. Comparison of severe acute respiratory syndrome coronavirus 2**  
431 **(SARS-CoV-2)-specific immunity at week 3 between the 21 fatal cases and 18**  
432 **survival cases of critical COVID-19.** The graph showed the percentage of  
433 SARS-CoV-2 specific IFN $\gamma$ +CD4+T cells (A), SARS-CoV-2 specific IFN $\gamma$ +CD8+  
434 T cells (B) and IgG titers (C). \*\*\*\*,  $P < 0.0001$ .

435

436




Figure 1

437

438




Figure 2

439




Figure 3

440




Figure 4

441

442




Figure 5

443

444





Figure 6


445

446



447

448



449

450






Figure 9

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465 **Supplemental Materials**

466

467 **Table S1. Demographic characteristics of 35 fatal patients with COVID-19 on admission**

<b>Characteristics</b>	<b>Patients</b>
<b>Age, Median (IRQ), years</b>	64.0 (45.0-73.0)
<b>Gender</b>	
Male	24 (68.6%)
Female	11 (31.4%)
<b>Comorbidities</b>	
Hypertension	11 (31.4%)
Cardiovascular diseases	7 (20.0%)
Diabetes	6 (17.1%)
<b>Main symptoms</b>	
Fever	30 (85.7%)
Cough	18 (51.4%)
Fatigue	6 (17.1%)

468


469

470 **Table S2. Spearman's correlation test and mean of lymphocyte subsets in 25,239**  
471 **healthy controls**

472

<b>Age</b>	<b>CD3<sup>+</sup></b>	<b>CD4<sup>+</sup></b>	<b>CD8<sup>+</sup></b>	<b>CD4<sup>+</sup>/CD8<sup>+</sup></b>	<b>CD19<sup>+</sup></b>	<b>CD16<sup>+</sup>CD56<sup>+</sup></b>
year	cells/mm <sup>3</sup>	cells/mm <sup>3</sup>	cells/mm <sup>3</sup>	ratio	cells/mm <sup>3</sup>	cells/mm <sup>3</sup>
<b>16-19</b>	1835	857	621	1.24	304	257
<b>20-29</b>	1648	876	594	1.49	279	180
<b>30-39</b>	1502	852	526	1.64	247	188
<b>40-49</b>	1417	829	465	1.81	238	189
<b>50-59</b>	1379	822	428	1.92	237	200
<b>60-69</b>	1309	763	421	1.84	230	244
<b>70-79</b>	1220	718	391	1.82	210	265
<b>80-91</b>	938	530	348	2.09	166	304
<b>R</b>	-1	-0.9762	-1	0.9048	-1	0.6429
<b>P</b>	<0.0001	0.0004	<0.0001	0.0046	<0.0001	0.0962

473



474

475 **Figure S1. A representative flow cytometry gating strategy.**

476

477

478

479

480

481

482

483

484

485

486

487

488

489 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

490 **Study Design and Participants**

491 This retrospective study was conducted at Chinese PLA General Hospital, Peking Union Medical  
492 College Hospital, the First Affiliated Hospital, and affiliated hospitals of Shanghai University of  
493 Medicine and Health Sciences. Chinese PLA General Hospital and Peking Union Medical College  
494 Hospital are the largest clinical research hospitals in China. Demographic characteristics of 35  
495 fatal patients with COVID-19 on admission were listed in Table S1. The 18 critical cases (matched  
496 by age and sex) who survived were enrolled for comparison. This case series was approved by the  
497 institutional ethics board of Chinese PLA General Hospital (#2020-111), Peking Union Medical  
498 College Hospital (#ZS-1830), The First Affiliated Hospital (#KY2020046), and Shanghai  
499 University of Medicine and Health Sciences (#2019-LCHZ-18-20190507). Written informed  
500 consent was obtained from healthy controls and waived to COVID-19 patients due to the rapid  
501 emergence of this infectious disease. Identification of hypertensive patients was achieved by  
502 reviewing and analyzing available electronic medical records and patient care resources. Clinical  
503 outcomes (discharge, mortality, and recovery, etc.) were monitored and all clinical recovery  
504 hypertensive patients meet the following criteria: body temperature returned to normal for more  
505 than 3 days, respiratory symptoms improved significantly, and lung imaging showed significant  
506 improvement.

507

508 **METHOD DETAILS**

509 **Cell preparation**

510 Whole blood was centrifuged for 15 min at 1800 rpm to separate the cellular fraction and plasma.

511 The plasma was then carefully removed from the cell pellet and stored at -20°C. Peripheral blood  
512 mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS density gradients (GE  
513 Healthcare Life Sciences, USA) according to the manufacturer's instructions. Isolated PBMCs  
514 were either studied directly or cryopreserved in cell recovery media containing 10% DMSO  
515 (Gibco, USA), supplemented with 10% heat inactivated fetal bovine serum and stored in liquid  
516 nitrogen until used in the assays. Cryopreserved PBMCs were thawed by diluting them in 10 mL  
517 complete RPMI 1640 with 5% human AB serum (Gemini Bioproducts, USA) in the presence of  
518 benzonase (final concentration at 50 U/mL) before an experiment.

#### 519 **SARS-CoV-2 Spike glycoprotein peptide pools**

520 SARS-CoV-2 Spike glycoprotein peptide pools (SPs) were from Genscript Biotech, USA. SPs  
521 include 316 peptides (delivered in two subpools of 158 peptides) derived from a peptide scan (15  
522 mers with 11 amino acid overlap) through the entire Spike glycoprotein of SARS-CoV-2.

#### 523 **Expansion of PBMCs *in vitro***

524 20% of PBMCs were pulsed with 10 µg/mL of the SPs for 1 hour at 37 °C, subsequently washed,  
525 and cocultured with the remaining cells in AIM-V medium (Gibco; Thermo Fisher Scientific,  
526 USA) supplemented with 2% AB human serum (Gibco; Thermo Fisher Scientific, USA). PBMCs  
527 were cultured for 7 days in the presence of 20 U/mL of recombinant IL-2 (R&D Systems, USA).

#### 528 **Intracellular cytokine staining (ICS) assay**

529 PBMCs were first stimulated with or without SPs (2 µg /mL) for 3 h at 37°C, then brefeldin A (10  
530 µg/mL, Sigma-Aldrich, USA) was added to cultures to enable intracellular proteins to accumulate  
531 in all stimulations. PBMCs were stimulated RPMI medium containing 10% FCS as a negative  
532 control. After incubation for a total of 6 h, the cells were washed, fixed, permeabilized using

533 fixation/permeabilization solution kit (BD Biosciences, USA) and blocked with FcR blocking  
534 reagent (MoltenBio, USA) for 30 min at 4 °C to reduce nonspecific binding of antibodies to  
535 human Fc receptor. The cells were then stained with anti-IFN $\gamma$  antibodies (BD Bioscience, USA)  
536 for 30 min at 4 °C. After staining, all samples were washed twice with phosphate buffered saline  
537 (PBS) containing 0.1% saponin, 0.1% BSA and 0.05% NaN<sub>3</sub> (Sigma-Aldrich, USA), and  
538 resuspended in 300  $\mu$ L PBS for measurement in a flow cytometer (FACSVerse™ flow cytometry,  
539 BD Bioscience, USA).

540 **Real-time reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2**

541 Throat, sputum and blood samples were collected for extracting SARS-CoV-2 RNA from  
542 hypertensive patients suspected of having SARS-CoV-2 infection. In brief, RNA was extracted  
543 within 2 h using the total RNA isolation kit. Cell lysates (250  $\mu$ L) were transferred into a  
544 collection tube followed by vortex for 10 s. After standing at room temperature for 10 min, the  
545 collection tube was centrifugated at 1000 rpm for 5 min. The suspension was used for RT-PCR  
546 assay of SARS-CoV-2 RNA. Two target genes, including open reading frame 1ab (ORF1ab) and  
547 nucleocapsid protein (N), were simultaneously amplified and tested during the RT-PCR assay.  
548 The sequences of primers and probes were: Target 1 (ORF1ab): forward primer  
549 CCCTGTGGGTTTTACTTAA; reverse primer ACGATTGTCATCAGCTGA; and the probe  
550 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'. Target 2 (N): forward primer  
551 GGGGAATTCTCCTGCTAGAAT; reverse primer CAGACATTTGCTCTCAAGCTG; and  
552 the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. The RT-PCR assay was  
553 performed using a SARS-CoV-2 nucleic acid detection kit. Reaction mixture contained 12  $\mu$ L of  
554 reaction buffer, 4  $\mu$ L of enzyme solution, 4  $\mu$ L of probe primer solution, 3  $\mu$ L of diethyl

555 pyrocarbonate-treated water, and 2  $\mu$ L of RNA template. The RT-PCR assay was performed  
556 under the following conditions: incubation at 50 °C for 15 min and 95 °C for 5 min, 40 cycles of  
557 denaturation at 94 °C for 15 s, and extending and collecting fluorescence signal at 55 °C for 45 s.  
558 A cycle threshold value ( $C_t$ -value) less than 37 was defined as a positive test result, and a  $C_t$ -value  
559 of 40 or more was defined as a negative test. These diagnostic criteria were based on the  
560 recommendation by the National Institute for Viral Disease Control and Prevention (China).  
561 Samples with a  $C_t$ -value of 37 to less than 40 was confirmation by retesting. The copies of RNA  
562 per reaction were obtained from the standard curve of limiting-dilution series of standard copies of  
563 RNA versus PCR amplification cycle.

#### 564 **Enzyme-linked immunosorbent assay (ELISA) of immunoglobulin (Ig)**

565 Antibodies (IgM, IgA, and IgG) specific to SARS-CoV-2 were determined with two different  
566 ELISA: an in-house assay using SARS-CoV-2 Receptor Binding Domain (RBD) protein (Cat.  
567 #Z03479, Genscript Biotech, USA) as an antigen, or a commercial kit (SARS-CoV-2 Spike RBD  
568 ELISA Kit, Cat. #40591-V08H, Sino Biological, China). Microtiter plates were coated with 50  
569 ng/well of target protein overnight at 4 °C. Plates were then blocked for 2 h at 37 °C using 200  $\mu$ L  
570 of 5% non-fat milk in PBS. Serum samples were then diluted into 1:50 using PBS and 100  $\mu$ L of  
571 each sample was applied to coated ELISA plate and incubated for 2 h at 37 °C. Plates were then  
572 washed with PBS and incubated with HRP-labeled anti-human IgM, IgA, and IgG (Sigma Aldrich,  
573 USA), which were diluted to 1:2000 in 5% non-fat milk in PBS. After incubation for another 1 h  
574 at room temperature, the plates were washed and developed with TMB/E substrate (Millipore,  
575 USA). Finally, the reaction was stopped with 1 M  $H_2SO_4$ , and the optical density (OD) at 450 nm  
576 was measured. Negative serum control was run each time when the assay was performed. A

577 sample is positive if its adjusted OD value (OD of test – OD of control) exceeds the mean plus 3  
578 standard deviations of the normal controls.

#### 579 **Flow cytometry analysis**

580 All samples were analyzed by FACSVerse™ flow cytometry (BD Bioscience, USA). Two blood  
581 samples in two tubes (100 µL each) were stained according to the manufacturer's instructions.  
582 Then, red-cell lysis buffer (1 mL) was added to each tube, the samples were incubated for 10 min  
583 and washed with Sorvall cell washer (Thermo Fisher Scientific, USA). Cells were blocked with  
584 FcR blocking reagent (MoltenBio, USA) for 30 min at 4 °C to reduce nonspecific binding of  
585 antibodies to human Fc receptor and washed with PBS. The cells were then stained with  
586 antibodies as listed in Figure and the fixable dead cell stain kit (Invitrogen, USA) for 30 min at  
587 4 °C and were then resuspended in 350 µL PBS and analyzed in flow cytometry (FACSVerse™  
588 flow cytometry, BD Bioscience, USA). Calibration and quality control for the instrument were  
589 carried out daily with the use of eight-color setup beads (BD Bioscience). All specimens were  
590 analyzed in duplicates with coefficient of variation (CV) < 5% by two independent technicians  
591 under the inter-laboratory quality control. The experiments were repeated if the results showed  
592 CV > 5% according to the instructions of BD Bioscience. The data were analyzed by FlowJo  
593 software (version 10, Tree Star, USA).

#### 594 **Statistical analysis**

595 Categorical variables were described as frequency rates and percentages, and continuous variables  
596 were described using mean and median values. Means for continuous variables were compared  
597 using independent group *t* tests when the data were normally distributed; otherwise, the  
598 Mann-Whitney test was used. Data (non-normal distribution) from repeated measures were



599 compared using the generalized linear mixed model. Proportions for categorical variables were  
600 compared using the  $\chi^2$  test, although the Fisher's exact test was used when the data were limited.  
601 All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences  
602 Inc., version 13.0). For unadjusted comparisons, a two-sided *P* value less than 0.05 was  
603 considered statistically significant. The analyses have not been adjusted for multiple comparisons  
604 and, given the potential for type I error, the findings should be interpreted as exploratory and  
605 descriptive. Because the cohort of patients in our study was not derived from random selection, all  
606 statistics are deemed to be descriptive only.  
607  
608